Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted psychotherapy for borderline personality disorder with PTSD
ACTRN12624000871549Phase 2Not yet recruiting
- Sponsor
- Spectrum Personality Disorder Service
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of midomafetamine in borderline personality disorder (BPD), post-traumatic stress disorder (PTSD) and complex post-traumatic stress disorder (cPTSD) (2 arms), sponsored by Spectrum Personality Disorder Service. Primary endpoints: Safety, Feasibility from the perspectives of Spectrum clinicians and 2 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
midomafetamine
03
Conditions
borderline personality disorder (BPD)post-traumatic stress disorder (PTSD)complex post-traumatic stress disorder (cPTSD)
Beyond the preview
Go deeper on ACTRN12624000871549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000871549.